Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc (TSX: ONC )

1.660 +0.070 (+4.40%)
Streaming Delayed Price Updated: 3:59 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oncolytics Biotech Inc

< Previous 1 2 3 4 Next >
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 10, 2021 – USA News Group – Nearly 10% of the estimated ~1.9 million new cancer cases in the USA will be diagnosed as... 
Via FinancialNewsMedia
The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026
Palm Beach, FL – December 21, 2021 – FinancialNewsMedia.com News Commentary – Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the... 
Via FinancialNewsMedia
Oncolytics Biotech® Promotes Thomas C. Heineman, M.D., Ph.D., to Chief Medical Officer
Dr. Heineman has over two decades of experience successfully leading clinical development programs and previously served as Oncolytics’ Global Head of Clinical Development and Operations SAN DIEGO, CA... 
Via FinancialNewsMedia
Ongoing R&D Leading to Discovery of More Efficient Therapies for Acute Myeloid Leukemia Therapeutics
Palm Beach, FL – December 15, 2021 – FinancialNewsMedia.com News Commentary – Acute Myeloid Leukemia (AML) is a type of blood cancer which usually affects white blood cells (WBCs), however, it can also... 
Via FinancialNewsMedia
Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the Synergistic Anti-Leukemic Effects of Pelareorep Combined with Azacitidine at the 2021 American Society of Hematology Annual Meeting
Treatment with intravenous pelareorep plus azacitidine reduced tumor burden Treatment with pelareorep and azacitidine dramatically upregulated multiple genes known to drive anti-cancer immune responses... 
Via FinancialNewsMedia
Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 10, 2021 – USA News Group – Researchers led by a scholar from City University of Hong Kong (CityU) have developed a novel... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Big Trend Occurring in Triple-Negative Breast Cancer Treatment Is The Shift Towards Combination Therapy
Palm Beach, FL – December 10, 2021 – FinancialNewsMedia.com News Commentary – Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options... 
Via FinancialNewsMedia
Oncolytics Biotech® Presents Positive Interim Safety Update from Phase 2 Triple-Negative Breast Cancer Trial at the 2021 San Antonio Breast Cancer Symposium
No safety concerns have been noted in any trial participants Trial builds on prior clinical data demonstrating pelareorep’s ability to reverse immunosuppressive tumor microenvironments and upregulate... 
Via FinancialNewsMedia
Drug Combinations and New Approvals Delivering Optimistic Results in Oncology Stocks
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 8, 2021 – USA News Group – Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit... 
Via FinancialNewsMedia
Promising New Developments Causing Some Biotech Stocks to Pull Away from Underperforming Peers
FN Media Group Presents USA News Group News Commentary Vancouver, BC –October 14, 2021 – USA News Group – Compared to the Dow Jones Industrial Average which has gained an impressive 10.6% through Q3... 
Via FinancialNewsMedia
Topics Stocks
Exposures US Equities
Oncolytics Biotech® Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Trial is designed to advance pelareorep’s clinical development in China, the world’s second-largest pharmaceutical market San Diego, CA and Calgary, AB – October 14, 2021 — Oncolytics Biotech® Inc.... 
Via FinancialNewsMedia
Global Metastatic Cancer Treatment Market Size Is Forecasted To Reach $111.16 Million By 2027
Palm Beach, FL – November 3, 2021 – FinancialNewsMedia.com News Commentary – The metastatic cancer treatment systems market is observing high demand attributed to its increasing application in breast,... 
Via FinancialNewsMedia
New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space
Via FinancialNewsMedia
Accelerating R&D Activities in Breast Cancer Therapy Market Fueling Optimism for Development of Advanced Treatments
Palm Beach, FL – October 14, 2021 – FinancialNewsMedia.com News Commentary – The breast cancer drugs market, which has been steadily growing over the past few years, is projected to continue this trend... 
Via FinancialNewsMedia
Exposures COVID-19
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment
Via FinancialNewsMedia
Topics Death
Exposures Death
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026
Via FinancialNewsMedia
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.